The impact of T-cell immunity on ovarian cancer outcomes.
about
Human perforin mutations and susceptibility to multiple primary cancersTranslational implications of tumor heterogeneityB7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer lookImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerInvasive Growth Hormone Producing Pituitary Adenoma With Lymphocytic Infiltration: A Case Report and Literature Review.Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsNeo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironmentPolyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.Prognostic impact of lymphocytes in soft tissue sarcomasβ-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasisAb-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsPlasma immune analytes in patients with epithelial ovarian cancer.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model.Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytesImmunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.Monocyte and interferon based therapy for the treatment of ovarian cancer.The effectiveness of postoperative neutrophils to lymphocytes ratio in predicting long-term recurrence after stomach cancer surgery.Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulationIL-27 induces the expression of IDO and PD-L1 in human cancer cells.Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsGetting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.p53 autoantibodies, cytokine levels and ovarian carcinogenesisImmune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors.Targeting CCL11 in the treatment of ovarian cancer.Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.Peritoneal immune system in patients with advance epithelial ovarian cancer.
P2860
Q24627596-A99AB168-F7F1-4BA3-A7FF-34F919DF0F91Q26822823-76255810-60EF-425C-B79C-3002B919AF6AQ26824446-86F07AAC-1DE6-4943-AD42-5B9DC784DA22Q26996829-FF3C3500-0F1C-47CD-8B74-C27154F1C8FAQ31043574-A5F1DB9B-CEC6-41E7-A5EC-9A7E42FF1DFFQ33377058-DBEC6353-507B-4D45-8EF6-C0895A3CB0BEQ33488520-9FCA28F1-F26E-4BFA-8143-72BEBD5F6DF8Q33564510-B824F7E1-15B6-4B43-B55F-979E23367772Q33586795-D7BBEFA9-4779-481C-9231-BD7AF1E318A7Q33671344-E074DAB8-FA8E-4FBF-A02D-DC0E10C9B69EQ33784707-2F6E62D4-C817-48ED-83D5-8CA00D6475D7Q33813250-B47B49F0-6418-486F-9F4B-94C29C34F1C3Q33929428-A21C7A3B-AE04-4C77-A2EF-5512AE137719Q34007762-15167D55-192B-4448-AF29-691247AA1297Q34110125-3CDDB6A4-1FFE-4057-9CBA-EA742E4FA644Q34129154-8D67E5DB-918B-4E62-9E98-1B234462728CQ34178740-339AA267-54A5-476C-B70B-B59C1F86016AQ34477550-713D51A1-4D50-49A7-A5BE-1C62B4A07E4AQ35236090-568BB2CA-B0DB-4D2B-807E-026655128461Q35506724-C2CB71F4-82DF-4053-986A-9797D7276E01Q35595605-3998EA4E-8192-45D8-A30C-701942161236Q35818203-32C4F101-58AA-4B2B-BD87-9302F45E6A96Q35847903-22F803F9-8496-4920-BF53-846F3AD934E9Q35861249-78B7C013-73B4-4F6B-B67C-3D1EAD82D44AQ35889643-B60AD260-5F6B-4539-9757-721FE691FE30Q35973378-232B955E-455B-4EB1-A150-F6C2F2894830Q36445533-2418EACD-153A-48F3-A647-93232D600FD8Q36673709-379022F9-5A15-477A-9390-214ECAB5AF00Q36685395-CE7A3F15-4B78-4EE1-84EB-897D6A65D9A8Q36769318-38242F8A-65EE-4FAB-A96B-FDDEAC55AE0AQ36839509-4B84ED0F-99B3-4B44-BF5F-4F46978E36B1Q37196532-C4BE97D2-B9A5-40DA-8CC6-F13B9403EA87Q37223836-46249CE9-1747-4BCC-9F70-CAAB6094E38CQ37224568-DF81BEE1-EE0E-47B5-9661-5AEF1F92A6B8Q37328373-81A06320-0231-4E18-94F4-3BBA54668545Q37375286-84261DCB-D8C9-4A29-81D9-BD52EF84FFDDQ37589128-715A5BF6-CA24-414D-8EBE-9F255B06D56CQ37670242-5588EF80-6D71-4AE7-A44D-4F891635B35FQ37709136-42E5B685-2307-4E7E-A863-D9A28C4CA124Q37873925-FB1D68A0-D298-4F18-8571-294042BFDA24
P2860
The impact of T-cell immunity on ovarian cancer outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The impact of T-cell immunity on ovarian cancer outcomes.
@en
The impact of T-cell immunity on ovarian cancer outcomes.
@nl
type
label
The impact of T-cell immunity on ovarian cancer outcomes.
@en
The impact of T-cell immunity on ovarian cancer outcomes.
@nl
prefLabel
The impact of T-cell immunity on ovarian cancer outcomes.
@en
The impact of T-cell immunity on ovarian cancer outcomes.
@nl
P2860
P1476
The impact of T-cell immunity on ovarian cancer outcomes.
@en
P2860
P304
P356
10.1111/J.1600-065X.2008.00614.X
P577
2008-04-01T00:00:00Z